scholarly journals Enhanced Prophylactic and Therapeutic Effects of Polylysine-Modified Ara h 2 DNA Vaccine in a Mouse Model of Peanut Allergy

2016 ◽  
Vol 171 (3-4) ◽  
pp. 241-250 ◽  
Author(s):  
Zhenlai Zhu ◽  
Jinlei Yu ◽  
Yuan Niu ◽  
Shuhong Sun ◽  
Yufeng Liu ◽  
...  
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Peanut Allergy ◽  
Therapeutic Effects ◽  
Ara H 2

PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia

10.1038/nm949 ◽  
2003 ◽  
Vol 9 (11) ◽  
pp. 1413-1417 ◽  
Author(s):  
Rose Ann Padua ◽  
Jerome Larghero ◽  
Marie Robin ◽  
Carol le Pogam ◽  
Marie-Helene Schlageter ◽  
...  
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Protective Immunity

scholarly journals Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31

2021 ◽  
Author(s):  
Danielle A. Simmons ◽  
Brian D. Mills ◽  
Robert R. Butler III ◽  
Jason Kuan ◽  
Tyne L. M. McHugh ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Treatment Response ◽  
Diffusion Tensor ◽  
Disease Onset ◽  
Therapeutic Effects ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Pharmacodynamic Biomarkers

AbstractHuntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomarkers. Multi-modal magnetic resonance imaging (MRI) and plasma cytokines have been suggested as disease onset/progression biomarkers, but their ability to detect treatment efficacy is understudied. This study used the R6/2 mouse model of HD to assess if structural neuroimaging and biofluid assays can detect treatment response using as a prototype the small molecule p75NTR ligand LM11A-31, shown previously to reduce HD phenotypes in these mice. LM11A-31 alleviated volume reductions in multiple brain regions, including striatum, of vehicle-treated R6/2 mice relative to wild-types (WTs), as assessed with in vivo MRI. LM11A-31 also normalized changes in diffusion tensor imaging (DTI) metrics and diminished increases in certain plasma cytokine levels, including tumor necrosis factor-alpha and interleukin-6, in R6/2 mice. Finally, R6/2-vehicle mice had increased urinary levels of the p75NTR extracellular domain (ecd), a cleavage product released with pro-apoptotic ligand binding that detects the progression of other neurodegenerative diseases; LM11A-31 reduced this increase. These results are the first to show that urinary p75NTR-ecd levels are elevated in an HD mouse model and can be used to detect therapeutic effects. These data also indicate that multi-modal MRI and plasma cytokine levels may be effective pharmacodynamic biomarkers and that using combinations of these markers would be a viable and powerful option for clinical trials.

scholarly journals A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xuejie Gao ◽  
Bo Li ◽  
Anqi Ye ◽  
Houcai Wang ◽  
Yongsheng Xie ◽  
...  
Keyword(s):  
Mouse Model ◽  
Tumor Burden ◽  
High Rate ◽  
Cell Counting ◽  
Tumor Xenograft ◽  
Luciferase Reporter ◽  
Therapeutic Effects ◽  
Xenograft Mouse Model

Abstract Background Multiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. In the current study, we intend to investigate the therapeutic effects of DCZ0805 in MM cells and elucidate the molecular mechanism underlying its anti-myeloma activity. Methods We used the Cell Counting Kit-8 assay, immunofluorescence staining, cell cycle assessment, apoptosis assay, western blot analysis, dual-luciferase reporter assay and a tumor xenograft mouse model to investigate the effect of DCZ0805 treatment both in vivo and in vitro. Results The results showed that DCZ0805 treatment arrested the cell at the G0/G1 phase and suppressed MM cells survival by inducing apoptosis via extrinsic and intrinsic pathways. DCZ0805 suppressed the NF-κB signaling pathway activation, which may have contributed to the inhibition of cell proliferation. DCZ0805 treatment remarkably reduced the tumor burden in the immunocompromised xenograft mouse model, with no obvious toxicity observed. Conclusion The findings of this study indicate that DCZ0805 can serve as a novel therapeutic agent for the treatment of MM.

scholarly journals Diagnostic accuracy of Ara h 2 for detecting peanut allergy in children

2021 ◽  
Author(s):  
Hannah M. Kansen ◽  
Francine C. van Erp ◽  
Yolanda Meijer ◽  
Dianne M.W. Gorissen ◽  
Marike Stadermann ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Peanut Allergy ◽  
Ara H 2

scholarly journals Immunocytes as a Biocarrier to Delivery Therapeutic and Imaging Contrast Agents to Tumors

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Jinhyang Choi ◽  
Ha-Na Woo ◽  
Eun Jin Ju ◽  
Joohee Jung ◽  
Hye-Kyung Chung ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Ionizing Radiation ◽  
Mouse Model ◽  
Cancer Treatment ◽  
Anticancer Agents ◽  
Anticancer Agent ◽  
Human Cancer ◽  
Genetic Alterations ◽  
Therapeutic Effects ◽  
Ionizing Radiation Exposure

Radiotherapy for cancer treatment has been used for primary or adjuvant treatment in many types of cancer, and approximately half of all cancer patients are undergoing radiation. However, ionizing radiation exposure induces genetic alterations in cancer cells and results in recruitment of monocytes/macrophages by triggering signals released from these cells. Using this characteristic of monocytes/macrophages, we have attempted to develop a biocarrier loading radiosensitizing anticancer agents that can lead to enhance the therapeutic effect of radiation in cancer treatment. The aim of this study is to demonstrate the proof of this concept. THP-1 labeled with Qdot 800 or iron oxide (IO) effectively migrated into tumors of subcutaneous mouse model and increased recruitment after ionizing radiation. Functionalized liposomes carrying a radiosensitizing anticancer agent, doxorubicin, are successfully loaded in THP-1 (THP-1-LP-Dox) with reduced cytotoxicity, and THP-1-LP-Dox also was observed in tumors after intravenous administration. Here, we report that monocytes/macrophages as a biocarrier can be used as a selective tool for amplification of the therapeutic effects on radiotherapy for human cancer treatment.

Development and Evaluation of a DNA Vaccine Based on Helicobacter pylori urease B: Failure to Prevent Experimental Infection in the Mouse Model

Helicobacter ◽  
2006 ◽  
Vol 11 (6) ◽  
pp. 517-522 ◽  
Author(s):  
Livania Zavala-Spinetti ◽  
Mary B. Breslin ◽  
Hernán Correa ◽  
Rodolfo E. Bégué
Keyword(s):  
Helicobacter Pylori ◽  
Mouse Model ◽  
Dna Vaccine ◽  
Experimental Infection
Sign in / Sign up

Export Citation Format

Share Document